论文部分内容阅读
目的探讨米非司酮配伍米索前列醇在绝经后妇女宫内节育器(intrauterine device,IUD)取出中的应用效果。方法 2008年1月—2011年1月要求取出IUD绝经后妇女112例,随机分为A组和B组各56例,A组:于术前3 d早、晚各服米非司酮25 mg,两次服药间隔12 h,服药前后空腹2 h,总量150 mg,手术当日术前2 h阴道后穹隆置米索前列醇400μg;B组:米索前列醇400μg术前晚置于阴道后穹隆,术前2 h舌下含化米索前列醇200μg。计数资料采用χ2检验,P<0.05为差异有统计学意义。结果宫颈软化率A组85.7%,B组62.5%,两组比较差异有统计学意义(P<0.05)。A组取器顺利89.3%,B组取器顺利64.3%,两组比较差异有统计学意义(P<0.05)。结论米非司酮配伍米索前列醇应用绝经后妇女取器,可提高手术成功率,减轻受术者痛苦,且安全有效、不良反应小,可作为绝经后妇女取器的术前用药。
Objective To investigate the effect of mifepristone and misoprostol on the removal of intrauterine device (IUD) in postmenopausal women. Methods From January 2008 to January 2011, 112 postmenopausal women with IUD were recruited and randomly divided into group A and group B (56 cases each). Group A: Mifepristone 25 mg , Twice a medication interval of 12 h, fasting 2 h before and after taking the medicine, the total amount of 150 mg, 2 h before surgery vaginal posterior dome placement of misoprostol 400μg; B group: misoprostol 400μg For the dome, 200 μg of misoprostol was sublingual 2 h preoperatively. Count data using χ2 test, P <0.05 for the difference was statistically significant. Results Cervical softening rate was 85.7% in group A and 62.5% in group B, with significant difference between the two groups (P <0.05). The successful rate of A and B was 89.3% and 64.3%, respectively. There was significant difference between the two groups (P <0.05). Conclusions Mifepristone and misoprostol can improve the successful rate of operation, relieve the pain of the affected patients, be safe and effective, and have less adverse reactions. Therefore, it can be used as a preoperative medication for postmenopausal women.